Prime Capital Investment Advisors LLC Has $7.53 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Prime Capital Investment Advisors LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,518 shares of the company’s stock after purchasing an additional 580 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Zoetis were worth $7,526,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. First Personal Financial Services acquired a new stake in Zoetis in the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Quarry LP raised its position in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. Fortitude Family Office LLC increased its holdings in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares during the last quarter. Finally, LRI Investments LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at approximately $43,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.2 %

Shares of NYSE ZTS opened at $173.95 on Wednesday. The business has a 50-day simple moving average of $188.00 and a two-hundred day simple moving average of $179.93. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a market cap of $78.48 billion, a P/E ratio of 32.70, a P/E/G ratio of 2.70 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 earnings per share. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. Research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ZTS shares. Stifel Nicolaus lifted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.